Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.43 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217998 | 0.86 | NR4A2 (0.47) | NR4A2SOS2F7F3DYRK1A | |
| SCHEMBL944985 | 0.76 | HTT (0.41) | CYP1A2LMNASMN1; SMN2CCNB2CDK1 | |
| SCHEMBL856993 | 0.76 | CCNC (0.35) | MAPTKMT2APARP1CCNB2CDK1 | |
| SCHEMBL1451142 | 0.76 | ALDH1A1 (0.41) | MAPTKMT2AALOX15CASP1HSD17B10 | |
| SCHEMBL4467255 | 0.76 | ALDH1A1 (0.46) | CYP1A2NPC1RAB9AKMT2ACCR1 | |
| SCHEMBL1496350 | 0.75 | MAPK13 (0.34) | DYRK1ACDK1 | |
| SCHEMBL12504891 | 0.73 | TTR (0.42) | DYRK1A | |
| SCHEMBL28141381 | 0.73 | — | — | |
| SCHEMBL590041 | 0.72 | LMNA (0.43) | CYP1A2NPC1RAB9AMAPTKMT2A | |
| SCHEMBL5748480 | 0.72 | ALDH1A1 (0.34) | NPC1RAB9ATDP1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338898-A | Small molecule inhibitors of oncogenic CHD1L with preclinical anti-colorectal cancer activity | 科罗拉多州立大学董事会（法人团体） | 2024-07-12 | — | — | CN | disclosed |
| WO-2023055763-A2 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTRAL CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230103444-A1 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | UNITED STATES GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| US-9320276-B2 | N-hetarylmethyl pyrazolylcarboxamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-26 | — | — | US | disclosed |
| US-20130225606-A1 | N-HETARYLMETHYL PYRAZOLYLCARBOXAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| EP-1539740-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539706-A1 | 1-SULPHONYL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004024721-A1 | HYDANTOIN DERIVATIVES UND DEREN VERWENDUNG ALS TACE INHIBITOREN | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024715-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024698-A1 | 1-SULPHONYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| WO-2004006926-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
| US-6660751-B1 | Sulfonamide derivatives as 5-HT7 receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-12-09 | — | — | US | disclosed |
| US-5051447-A | Applying aromatic oximes to plants, seeds or soils | BASF AKTIENGESELLSCHAFT (DE) | 1991-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | NR4A2 189/4885SOS2 2356/4885F7 4581/4885 |
| US-20230103444-A1 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | CHD1L, CHD1, CHD9 | NR4A2 264/4885SOS2 430/4885F7 3739/4885 |
| US-20130225606-A1 | N-HETARYLMETHYL PYRAZOLYLCARBOXAMIDES | CYP51A1, HDHD5, CYP4Z1 | NR4A2 862/4885SOS2 3722/4885F7 3828/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | NR4A2 62/4885SOS2 1635/4885F7 2743/4885 |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | MMP9, MMP2, MMP25 | NR4A2 2022/4885SOS2 1529/4885F7 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.